Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) serves as a potent inhibitor related to Pentamidine, targeting the calcium-binding protein S100B with a dissociation constant (Kd) of 6.9 µM. It demonstrates specificity by preferentially killing melanoma cells overexpressing S100B compared to cells lacking this protein. Additionally, Heptamidine is employed as a valuable research tool in the study of Myotonic dystrophy (DM).

S100B:(kd)6.9 μM

Heptamidine在HeLa细胞DM1模型中纠正minigene报告基因片段剪接错误（EC50：15 μM）。与Propamidine和Pentamidine相比，Heptamidine（20 μM）并未显著降低CUG水平，且在表达960个CUG重复序列的HeLa细胞中，浓度超过17.5 μM时表现出细胞毒性[2]。

Heptamidine（i.p.；20或30 mg/kg；7天）在HSALR小鼠中引起剂量依赖性的exon 7a含量减少，20 mg/kg剂量时回复至野生型水平（6±1%），同时肌阵挛从3级（频繁的肌阵挛放电）降低至1级（偶尔的肌阵挛放电）[2]。